Anyone with an involvement or interest in clinical research is likely to be aware of the challenges sponsors face in getting their compounds approved by the FDA. The low rates at which drugs make it all the way through the research process is a favorite topic of blogs and journalistic outlets covering clinical research. Many of the drugs that fall by the wayside suffer that fate because of unfavorable efficacy data in the middle and later phases.(1) Many others, though, fall victim to administrative or technical challenges - and these issues often arise not as a compound nears the finish line, but as early as the nascent stages of Phase I. Here are three obstacles that researchers commonly face early in Phase I, as well as some insight into how the right eClinical software can nip some of those obstacles in the bud.